116649-85-5 Usage
Uses
Used in Pharmaceutical Industry:
Ramatroban is used as a thromboxane receptor antagonist for the treatment of coronary artery disease. It blocks the contractions induced by thromboxane or TxA2-mimetics in animal and human airway smooth muscle, preventing bronchoconstriction induced by PGD2 or antigen when administered intravenously, orally, or by aerosol.
Used in Allergy Treatment:
In the field of allergy treatment, Ramatroban is used to alleviate symptoms of allergic rhinitis. It inhibits antigen-induced neutrophil infiltration into nasal mucosa and reduces nasal symptoms in animal models of nasal allergy.
Originator
Bayer (Germany)
Biological Activity
Potent dual antagonist of TP/DP 2 (CRTH2) prostanoid receptors (K i values are 4.3, 4.5 and > 10000 nM for hDP 2 , hTP and hDP 1 receptors respectively). Suppresses PGD 2 -induced migration of human eosinophils (IC 50 = 170 nM).
in vitro
bay u3405 showed significant inhibitory effects on the binding of 3h-labeled pgd2 to crth2, albeit with much lower potency. bay u3405 and indomethacin also inhibited pgd2-induced ca2+ mobilization in crth2 transfectants to almost the same extent. however, indomethacin but not bay u3405 was confirmed as an agonist of ca2+ mobilization at concentrations greater than 10 nm [1].
in vivo
for rat with splanchnic artery occlusion shock, administration of bay u3405 at 30 mg/kg i.v. could significantly increase the survival time and survival rate, improve mean arterial blood pressure, reduce the plasma levels of myocardial depressant factor, partially restore macrophage phagocytosis and lower mpo activity in both the ileum and the lung [2].
IC 50
100-170 nm
references
[1] sugimoto, h. ,shichijo, m.,iino, t., et al. an orally bioavailable small molecule antagonist of crth2, ramatroban (bay u3405), inhibits prostaglandin d2-induced eosinophil migration in vitro. journal of pharmacology and experimental therapeutics 305, 347-352 (2003).[2] canale p, squadrito f, altavilla d, ioculano m, campo gm, squadrito g, urna g, sardella a, caputi ap. beneficial effects of bay u3405, a novel thromboxane a2 receptor antagonist, in splanchnic artery occlusion shock. pharmacology. 1994 dec;49(6):376-85.[3] aizawa h, shigyo m, nogami h, hirose t, hara n. bay u3405, a thromboxane a2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. chest. 1996 feb;109(2):338-42.
Check Digit Verification of cas no
The CAS Registry Mumber 116649-85-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,6,4 and 9 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 116649-85:
(8*1)+(7*1)+(6*6)+(5*6)+(4*4)+(3*9)+(2*8)+(1*5)=145
145 % 10 = 5
So 116649-85-5 is a valid CAS Registry Number.
InChI:InChI=1/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
116649-85-5Relevant academic research and scientific papers
Asymmetric chemoenzymatic synthesis of ramatroban using lipases and oxidoreductases
Busto, Eduardo,Gotor-Fernandez, Vicente,Gotor, Vicente
, p. 4842 - 4848 (2012/07/31)
A chemoenzymatic asymmetric route for the preparation of enantiopure (R)-ramatroban has been developed for the first time. The action of lipases and oxidoreductases has been independently studied, and both were found as excellent biocatalysts for the production of adequate chiral intermediates under very mild reaction conditions. CAL-B efficiently catalyzed the resolution of (±)-2,3,4,9-tetrahydro-1H-carbazol-3-ol that was acylated with high stereocontrol. On the other hand, ADH-A mediated bioreduction of 4,9-dihydro-1H-carbazol-3(2H)-one provided an alternative access to the same enantiopure alcohol previously obtained through lipase-catalyzed resolution, a useful synthetic building block in the synthesis of ramatroban. Inversion of the absolute configuration of (S)-2,3,4,9-tetrahydro-1H-carbazol-3-ol has been identified as a key point in the synthetic route, optimizing this process to avoid racemization of the azide intermediate, finally yielding (R)-ramatroban in enantiopure form by the formation of the corresponding amine and the convenient functionalization of both exocyclic and indole nitrogen atoms.
Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid and comparison with its enantiomer
Rosentreter,Boshagen,Seuter,Perzoborn,Fiedler
, p. 1519 - 1521 (2007/10/02)
The synthesis of (3R)-3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid (Bay u 3405), a new, enantiomerically pure antagonist of thromboxane A2, is described. The determination of the absolute configuration of Bay u 3405 was performed by an X-ray analysis of compound 7 ([3((2S)-acetylamido)-3-phenylpropionamido]- 1,2,3,4-tetrahydro-carbazol). Bay u 3405 is in vitro 1 to 2 orders of magnitude more acitve than its (-)-enantiomer Bay u 3406.